The Vaccine Community Connectors program announced it plans to vaccinate two million American seniors. The pilot program, launched by a dozen health insurers, is designed to educate seniors, assist in setting up appointments and provide transportation for vaccination. (CNBC Weekly)

New studies show a COVID variant found in Brazil was able to reinfect people who have already recovered from the virus. The variant, P.1, has spread to 24 other countries, including the U.S. (The New York Times)

Ovid Therapeutics is selling its rights to soticlestat, which treats developmental and epileptic encephalopathies, to Takeda for $196 million in cash and up to $660 million more if certain milestones are hit. Ovid said the funds will pave the way for new ventures in rare neurological diseases. (STAT)

In order to make vaccination efforts easier in the future, companies are exploring new delivery alternatives, like microneedle patches and nasal sprays. Most of the products, like Enesi’s dissolving implants, are in the early stages of development and clinical testing. (The Wall Street Journal)

United Therapeutics has halted development of pulmonary arterial hypertension drug Trevyent. The move comes after the Food and Drug Administration asked the company to redesign the product and conduct a new clinical study. (Endpoints News)